Abstract:Background Liver disease is a major cause of death and disability. Mesenchymal stem cells (MSCs) show promise for the treatment of liver disease. However, whether MSC-based therapy is more effective than conventional treatment is unclear, as are the optimal MSC source, the administration frequency, and the most effective MSC delivery route. We therefore undertook a systematic review and meta-analysis of the therapeutic efficacy of MSCs against liver disease and the related factors. Methods We systematically searched Medline (PubMed), Cochrane Library, EMBASE, ClinicalTrials.gov, and SinoMed CBM to identify studies published up to June 2017 involving liver disease patients receiving MSC-based therapy and which reported estimates of liver function during the follow-up period. Results Thirty-nine studies were selected from 672 publications. According to a meta-analysis of 23 controlled studies, compared with conventional treatment MSC therapy significantly improves liver function in patients with liver disease in terms of the model of end-stage liver disease score, albumin, alanine aminotransferase, and total bilirubin levels, and prothrombin time, up to 6 months after administration. However, it has no beneficial effects in terms of prothrombin activity, international normalized ratio, or cholinesterase level. Considerable heterogeneity was identified at most time points. Subgroup analyses showed that a single MSC injection was more effective than multiple injections, MSC administration was more effective via the hepatic artery than the peripheral vein, and MSCs derived from bone marrow were more effective than those derived from the umbilical cord. Conclusions MSC-based therapy is relatively safe and improves liver function during the first 6 months after administration. A single injection administration via the hepatic artery and MSCs derived from bone marrow are optimal in terms of improving liver function. However the significant heterogeneity among studies and discontinuous results of the subgroup meta-analysis should be addressed; moreover the long-term efficacy of MSC therapy warrants further investigation.

Mesenchymal stem cells-based therapy in liver diseases

Multiple Dimensions of Using Mesenchymal Stem Cells for Treating Liver Diseases: from Bench to Beside.

Pre-treatments enhance the therapeutic effects of mesenchymal stem cells in liver diseases

Mesenchymal stem cell homing to improve therapeutic efficacy in liver disease

A pooled analysis of mesenchymal stem cell-based therapy for liver disease

The Application of Mesenchymal Stem Cells in the Treatment of Liver Diseases: Mechanism, Efficacy, and Safety Issues

Current understanding of adipose-derived mesenchymal stem cell-based therapies in liver diseases

Recent advances in the immunomodulation mechanism of mesenchymal stem cell therapy in liver diseases

Mesenchymal stem cell therapy for liver transplantation: clinical progress and immunomodulatory properties

Genetic modification by overexpression of target gene in mesenchymal stromal cell for treating liver diseases

Current Status and Future Prospects of Mesenchymal Stem Cell Therapy for Liver Fibrosis

Mesenchymal stromal cells promote liver regeneration through regulation of immune cells

Application of Mesenchymal Stem Cells in Liver Fibrosis and Regeneration

Mesenchymal Stem Cell-Derived Extracellular Vesicles in Liver Immunity and Therapy

The clinical application of mesenchymal stem cells in liver disease: the current situation and potential future

Mesenchymal stem cell-based cell-free strategies: safe and effective treatments for liver injury

Immunomodulatory role of mesenchymal stem cell therapy in liver fibrosis

Improvement of mesenchymal stromal cells and their derivatives for treating acute liver failure

Mesenchymal stromal cells: promising treatment for liver cirrhosis

Strategies to improve the efficiency of mesenchymal stem cell transplantation for reversal of liver fibrosis

Immunological Basis of Stem Cell Therapy in Liver Diseases